{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:45Z","timestamp":1786991625378,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jceh.2019.07.012","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:35:42Z","timestamp":1564745742000},"page":"588-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field"],"prefix":"10.1016","volume":"9","author":[{"given":"Iliana","family":"Doycheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Thuluvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2019.07.012_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","article-title":"Global trends and predictions in hepatocellular carcinoma mortality","volume":"67","author":"Bertuccio","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A\u00a0meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.07.012_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/hep.27388","article-title":"Emerging trends in hepatocellular carcinoma incidence and mortality","volume":"61","author":"Njei","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.07.012_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397918-6.00001-X","article-title":"Catalytic mechanisms and regulation of protein kinases","volume":"548","author":"Wang","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jceh.2019.07.012_bib6","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.jceh.2019.07.012_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jceh.2019.07.012_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jceh.2019.07.012_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.07.012_bib11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib12","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jceh.2019.07.012_bib13","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jceh.2019.07.012_bib14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.07.012_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.07.012_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10637-018-0640-7","article-title":"Hand-foot-skin reaction of grade >\/= 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC","volume":"37","author":"Wang","year":"2019","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jceh.2019.07.012_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.15088","article-title":"Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib","volume":"49","author":"Diaz-Gonzalez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.07.012_bib21","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.3748\/wjg.15.4582","article-title":"Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells","volume":"15","author":"Xiao","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.07.012_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12876-018-0849-0","article-title":"Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"l","key":"10.1016\/j.jceh.2019.07.012_bib23","article-title":"Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared to TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"36","author":"Kudo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib25","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0168-8278(18)30424-0","article-title":"The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial palliative cohort. [Abstract]","volume":"68","author":"Ricke","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.jceh.2019.07.012_bib27","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jceh.2019.07.012_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2019.07.012_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jceh.2019.07.012_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2019.07.012_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2019.07.012_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.07.012_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207132","article-title":"Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis","volume":"13","author":"Shlomai","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.07.012_bib34","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.07.012_bib35","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jceh.2019.07.012_bib36","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jceh.2019.07.012_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.07.012_bib38","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2016.4115","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score","volume":"3","author":"Zhu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.07.012_bib41","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2019.07.012_bib42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:26Z","timestamp":1760853926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688319302063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0973688319302063"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2019.07.012","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2019.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}